At 6.3% CAGR, the Middle East & Africa Structural Heart Market is Projected to be Worth US$ 927.25 million by 2028, says Business Market Insights

According to Business Market Insights research, the Middle East & Africa structural heart market was valued at US$ 643.90 million in 2022 and is expected to reach US$ 927.25 million by 2028, registering a CAGR of 6.3% from 2022 to 2028. Availability of innovative structural heart services and rise in the number of cardiovascular diseases and training programs are the factors attributed to the Middle East & Africa structural heart market expansion.

Transcatheter procedures lead to improvements in patients’ heart conditions in shorter a period compared to surgical intervention. In addition, minimally invasive procedures have reduced surgical and cardiopulmonary risks, which results in increased patient satisfaction. TAVR has gathered more attention due to its ability to offer a reasonable option for the treatment of degenerative aortic stenosis. Moreover, the recent developments in structural heart devices focus on indications, and results of left atrial appendage (LAA) and patent foramen ovale (PFO) closure to prevent cardioembolic stroke. A few of the technological advancements by the players in the Middle East & Africa Structural heart market. In February 2023, Medtronic announced the relaunch of its Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired RVOT. Evolut FX added new features to the existing Evolut platform to enhance ease of use and predictable valve deployment for physicians. In May 2022, Philips launched EchoNavigator 4.0, the new release of its image-guided therapy solution, for the treatment of structural heart disease. Echo Navigator 4.0 provides the users of Philips’ EPIQ CVXi interventional cardiology ultrasound system a control of live fusion-imaging on the company’s Image Guided Therapy System called “Azurion – platform.” In September 2021, Abbott received FDA approval for its Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease. With this new device, Abbott expanded its Epic surgical valve platform. In August 2021, CORCYM enrolled the first patient in the Mitral, Aortic, and Tricuspid Post-Market Study in a Real-World Setting, i.e., MANTRA. The first implantation was performed at Citta di Lecce Hospital in Italy with a Bicarbon aortic mechanical valve. Therefore, technological advancements are leading to new growth trends in the Middle East & Africa Structural heart market growth.

On the contrary, high cost of procedures systems hampers the Middle East & Africa structural heart market. 

Based on product, the Middle East & Africa structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. The occluders segment held 40.4% share of Middle East & Africa structural heart market in 2022, amassing US$ 259.83 million. It is projected to garner US$ 379.58 million by 2028 to expand at 6.5% CAGR during 2022–2028. 

Based on procedure, the Middle East & Africa structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. The heart valve stenosis segment held 45.3% share of Middle East & Africa structural heart market in 2022, amassing US$ 291.81 million. It is projected to garner US$ 405.10 million by 2028 to expand at 5.6% CAGR during 2022–2028.

Based on end user, the Middle East & Africa structural heart market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals segment held 49.3% share of Middle East & Africa structural heart market in 2022, amassing US$ 317.50 million. It is projected to garner US$ 468.00 million by 2028 to expand at 6.7% CAGR during 2022–2028.

Based on country, the Middle East & Africa structural heart market has been categorized into Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa. Our regional analysis states Saudi Arabia that the captured 40.5% share of Middle East & Africa structural heart market in 2022. It was assessed at US$ 260.84 million in 2022 and is likely to hit US$ 391.58 million by 2028, exhibiting a CAGR of 7.0% during 2022–2028.

Key players operating in the Middle East & Africa structural heart market are Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc, and Edwards Lifesciences Corp, among others.   

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com